直接抗病毒药物治疗对HCV相关分子检测的新需求

The new demands for HCV related clinical examinations for DAA treatment

丙型肝炎病毒是慢性肝病的致病因素之一,直接抗病毒药物(DAA)上市以来,慢性丙型肝炎的治疗领域发生了迅猛变化,世界卫生组织提出2030年消除病毒性肝炎的目标。然而,目前全球特别是我国,现有慢性丙型肝炎患者基数较大、未接受治疗者比例高、已接受治疗者药物使用不规范、特殊人群有效率不佳、病毒耐药突变等问题的存在,使得在治愈病毒性肝炎的道路上仍然存在着各种困难。本文结合慢性丙型肝炎诊疗共识的演变,谈谈丙肝病毒相关实验室检测在抗病毒治疗中的作用及意义,以进一步提高治疗效果,为完成消除病毒性肝炎的目标提供助力。

Hepatitis C virus (HCV) is one of leading causes for chronic liver diseases,the treatment area has been changed rapidly since direct acting antiviral agents (DAAs) were approved to treat patients with chronic HCV infection.To cure hepatitis in 2030 is the goal set by World Health Organization.However,globally,especially in China,there are still many difficulties needing to be resolved on the cure road of chronic hepatitis C,such as large patient population,high percentage of untreated patients,nonstandard DAA treatment,low efficacy of special groups,and resistance-associated variants in baseline,etc.This comment will focus on the new demands for HCV related clinical examinations for DAA treatment,so as to improve the treatment effectiveness and to help achieve the goal of eliminating viral hepatitis.